Table 1. Demographic, anthropometric, clinical characteristics and asthma history of non-atopic asthma patients of FENOMA study Table 1. Demographic, anthropometric, clinical characteristics and asthma history of non-atopic asthma patients of FENOMA study
Variable N=80
Age, years, mean (SD) 58.7 (12.2)
Sex, female, n (%) 52 (65.0)
Smoking status, n (%) Never smoked Former (≥1 year) Time since having quit smoking, years, mean (SD) Current smoker Packages/year, mean (SD) 61 (76.2) 13 (16.2) 11.7 (5.1) 6 (7.5) 21.5 (21.3)
Asthma history in the year before starting treatment with omalizumab Asthma history in the year before starting treatment with omalizumab
Time since diagnosis of: Asthma, years, median (Q1;Q3) Severe persistent asthma, years, median (Q1;Q3) 12.9 (8.3; 23.3) 5.7 (4.4; 7.8)
Daytime symptoms, n (%)a No symptoms or symptoms ≤2 times a week >2 times a week Daily symptoms Continuous symptoms (several times a day) 3 (3.7) 15 (18.7) 43 (53.8) 18 (22.5)
Night-time symptoms, n (%)b No symptoms ≤2 times a month >2 times a month > 1 time a week Frequents 7 (8.9) 9 (11.4) 12 (15.2) 25 (31.6) 25 (31.6)
Need for rescue medication, n (%)a No or ≤2 days a week >2 days a week (but not every day) Every day Several times a day 6 (7.6) 22 (27.8) 41 (51.9) 10 (12.6)
Pulmonary function, median (Q1;Q3)a FEV1, %
69.0 (58.0; 79.0)
Non-severe asthma episodes, median (Q1;Q3) 5.0 (3.0; 8.0)
Severe or clinically significant exacerbations in the previous year, median (Q1;Q3)a 3.0 (2.0; 5.0)
Use of healthcare resources due to severe or clinically significant exacerbations, mean (SD) Visits to emergency unitsb Hospital admissions No. days of hospital stayc Intensive care units admission No. days of intensive care units stayd 3.0 (2.8) 1.0 (1.9) 6.8 (3.2) 0.2 (0.6) 5.4 (3.9)
Background treatments for asthma, n (%) ICS Dose, µg, median (Q1; Q3) OCSe Dose, mg, median (Q1; Q3) 80 (100.0) 800 (640,0; 1,000.0) 54 (67.5) 25.0 (6.0; 50.0)
IgE levels, IU/mL, median (Q1;Q3) 187.50 (106,0; 399,0)